Bristol Myers Squibb Company $BMY Shares Purchased by Kinsale Capital Group Inc.

Kinsale Capital Group Inc. increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.4% in the fourth quarter, HoldingsChannel reports. The firm owned 179,364 shares of the biopharmaceutical company’s stock after acquiring an additional 10,724 shares during the quarter. Bristol Myers Squibb accounts for 1.6% of Kinsale Capital Group Inc.’s portfolio, making the stock its 25th biggest position. Kinsale Capital Group Inc.’s holdings in Bristol Myers Squibb were worth $9,675,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Man Group plc lifted its holdings in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after purchasing an additional 5,503,391 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Bristol Myers Squibb by 530.6% during the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after purchasing an additional 4,588,601 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Bristol Myers Squibb by 67.8% during the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock worth $444,682,000 after purchasing an additional 3,982,439 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Bristol Myers Squibb by 31.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock worth $669,012,000 after purchasing an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in shares of Bristol Myers Squibb by 56.0% during the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after purchasing an additional 3,396,041 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.5%

Shares of BMY opened at $57.04 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The stock has a market capitalization of $116.48 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.26. The stock has a 50 day moving average price of $58.63 and a 200 day moving average price of $55.35.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

Analysts Set New Price Targets

A number of research firms recently commented on BMY. Barclays began coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.31.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.